News

News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.

Featured news

Donanemab update: new Alzheimer’s disease treatment approved by the FDA

On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease.  Donanemab is the…

Published date:

Celebrating 40 years of ADI

This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.

Published date:

Roche to end DIAN-TU-001 study for rare Autosomnal dominant Alzheimer’s disease

Roche‌ ‌announces ‌ end of ‌DIAN-TU-001‌ ‌study‌ ‌after‌ ‌it‌ ‌failed‌ ‌to‌ ‌meets‌ ‌its‌ ‌primary‌ ‌endpoint‌ ‌in‌ ‌people‌ ‌who‌ ‌are‌ ‌affected‌ ‌by‌ ‌early‌ ‌onset‌ ‌Autosomal‌ ‌dominant‌ ‌Alzheimer’s‌ ‌disease.

Published date:
Paola Barbarino and AAJ at the G20 Health Ministers Meeting

Dementia given high priority at G20 Health Ministers Meeting

Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.

Published date: